Guggenheim Reaffirms Buy on DBV Technologies, Sets $51 Target as VITESSE Trial Confirms Efficacy
Guggenheim reiterated a Buy rating and a $51.00 price target on DBV Technologies after meetings with company leadership, noting alignment with regulators and recent positive clinical readouts. The stock has surged 411% over the past year; DBV is preparing for an important earnings update on March 5 amid ongoing regulatory and commercial execution r…